Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Aug 22, 2025 · CIK: 882361
Sentiment: neutral
Topics: 8-K, financials, disclosure
Related Tickers: APTO
TL;DR
APTO filed an 8-K on 8/22/25 covering Reg FD and financials.
AI Summary
Aptose Biosciences Inc. filed an 8-K on August 22, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and has its fiscal year end on December 31st. Its business address is in Toronto.
Why It Matters
This filing provides an update on Aptose Biosciences' regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, not indicating any specific new risks or material events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- August 22, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Aptose Biosciences Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 22, 2025.
What is Aptose Biosciences Inc.'s fiscal year end?
Aptose Biosciences Inc.'s fiscal year end is December 31.
What were Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-08-22 17:05:29
Filing Documents
- f8k_082225.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-005555.txt ( ) — 214KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_082225_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 22, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated August 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: August 22, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer